Table 2.
Preclinical studies of protein degrader presented at ASH 2023
| Compound | Modality | Target | Indication | Reference |
|---|---|---|---|---|
| NXD02 | PROTAC | BCL-XL | AML | [5] |
| WH25244, PZ18753b | PROTAC | BCL − 2/ BCL-XL | VR CLL | [6] |
| DT2216 | PROTAC | BCL-XL | JAK2-mut AML (post-MPN) | [7] |
| K-256 | PROTAC | BET | MYC/BCL2-related lymphoma | [8] |
| KT-333 | PROTAC | STAT3 |
VR AML, VR DLBCL |
[9] |
| Mezigdomide | molecular glue | Aiolos/Ikaros | MM | [10] |
| PinA1 | molecular glue | CK1α | AML | [11] |
AML, acute myeloid leukemia; VR, venetoclax-resistant; CLL, chronic lymphoma leukemia; mut, mutation; MPN, myeloproliferative neoplasm; DLBCL, diffuse large B-cell lymphoma; MM, multiple myeloma; BET: Bromo and extra terminal; STAT3: signal transducer and activator of transcription 3; CK1α: casein kinase 1α